Catalog: | C-FC-0543A |
Product Type: | FCM Antibody |
Size: | 20 tests/50 tests/100 tests/200 tests |
Reactivity: | Human |
Analysis mode: | FCM |
Host: | Mouse |
Isotype: | Mouse IgG2b, κ |
Alternate names: | CKRL3, CMKBR6, GPR29, STRL22,GPRCY4 |
Form: | Liquid |
Shipping: | Biological ice pack at 4℃ |
Storage: | 2-8℃ |
Conjugation: | APC |
Buffer: | PBS with 0.05% Proclin300, 1% BSA |
Swiss port: | P51684 |
Clone NO.: | G034E3 |
Recommended use: | Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. The amount of the reagent is suggested to be used 5 μL of antibody per test (million cells in 100 µL staining volume or per 100 µL of whole blood). Please check your vial before the experiment. Since applications vary, the appropriate dilutions must be determined for individual use. |
CCR6, also known as CD196/CCR6, is a chemokine receptor that is expressed on immature dendritic cells, B lymphocytes, and memory T cells. CCR6 binds CCL20, although members of the β defensin family also bind CCR6 with a lower affinity. CCR6 positive cells, and its ligand CCL20, have been detected in numerous organs, especially the secondary lymphoid organ. CCL20 is selectively made by the follicle-associated epithelium (FAE) overlying Peyers Patches (PPs) and isolated lymphoid follicles (ILFs). CCL20 contributes to the recruitment of CCR6-expressing B cells to these structures. In humans, CCR6 can function to mediate arrest of T cells on dermal endothelial cells and is highly expressed on T cells resident in both normal and psoriatic skin. CCR6 and/or CCL20 have been implicated in the pathogenesis of rheumatoid arthritis and inflammatory bowel disease. Human T cells that are able to produce IL-17 express CCR6. It suggests that CCL20 and CCR6 have a role in inflammatory diseases by recruiting Th17 cells to target tissues.
Copyright © 2024 Creative Biogene. All rights reserved.